hepatic sinus occlusive syndrome caused by pyrrolidine
Conditions
Interventions
Anticoagulant therapy group:low molecular heparin and/or warfarin
Routine basic treatment group:protecting liver function,improving microcirculation and diuresis
Sponsors
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
Eligibility
Sex/Gender
All
Age
15 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years old; 2. Patients diagnosised with acute stage PA-HSOS From January 2012 to December 2017, diagnostic criteria of PA-HSOS: Patients with a clear tacking history of pyrrolidine alkaloid plants ,three of the following situations occur: (1) abdominal distension, ascites, and Upper abdominal pain; (2) serum total bilirubin >17.1 umol/L; (3) pyrrole Protein compounds can be decteted in peripheral blood; (4) typical ultrasonography and CT manifestations (portal vein blood flow velocity <25cm/s, "flower spot" uneven enhancement can be seen in CT balanced period, etc.); (5) in liver biopsy pathology ,Small blood vessels and hepatic sinus have extensive hematopoiesis expansion which mainly occurs in III region of Liver acinus can be seen;
Exclusion criteria
Exclusion criteria: 1. combined with liver cancer or malignant tumor of other organs; 2. during the period of pregnancy or lactation; 3. most of the clinical data is missing.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Curative effect index; | — |
Countries
China
Contacts
Public ContactYuZheng Zhuge
Gulou Hospital Affiliated to Nanjing University Medical College
Outcome results
None listed